Skip to main content
Evidence Snapshot

Tyrosine-protein kinase JAK2

CHEMBL1649049 SINGLE PROTEIN Mus musculus
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:39Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL1649049
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Tyrosine-protein kinase JAK2 as ChEMBL target CHEMBL1649049, mapped to UniProt Q62120. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Tyrosine-protein kinase JAK2
SINGLE PROTEIN · Mus musculus
As of 2026-09-14
ChEMBL target ID
CHEMBL1649049
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
Q62120
Tyrosine-protein kinase JAK2
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Tyrosine-protein kinase JAK2 matters

As of 2026-09-14

Tyrosine-protein kinase JAK2 is reviewed as Tyrosine-protein kinase JAK2 (UniProt Q62120); the current evidence base includes 5 approved drugs, 79 compounds, and 32 assays, with lead potency reaching pChEMBL 8.0.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 5 approved drugs, 79 compounds, and 32 assays for this target. The dominant activity type is IC50. CHEMBL4748354 is the current potency anchor at pChEMBL 8.0.

Use CHEMBL4748354 as the tractability anchor when discussing potency (pChEMBL 8.0).

Activity source · ChEMBL 36 via Core Engine
5 approved pChEMBL 8.0
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Tyrosine-protein kinase JAK2 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q62120, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

79
Total Compounds
32
Total Assays
5
Approved Drugs
IC50: 74.0, EC50: 1.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL4748354
 8.0 IC50 —
No preferred name
CHEMBL4754856
 8.0 IC50 —
No preferred name
CHEMBL3116050
 7.9 IC50 —
No preferred name
CHEMBL4759953
 7.9 IC50 —
No preferred name
CHEMBL4756422
 7.6 IC50 —

Approved Drugs

Structure Compound First Approval
UPADACITINIB
CHEMBL3622821
 2019
TOFACITINIB
CHEMBL221959
 2012
RUXOLITINIB
CHEMBL1789941
 2011
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:39Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL1649049